Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.
Functionally inhibitory antibody to the plasma membrane complement inhibitor CD59 has been used to investigate control of the terminal complement proteins at the endothelial cell surface. Antibodies against purified human erythrocyte CD59 (polyclonal anti-CD59 and monoclonal antibodies [MoAbs] 1F1 and 1F5) were found to bind specifically to monolayers of cultured human umbilical vein endothelial cells, and by Western blotting to recognize an 18- to 21-Kd endothelial protein. When bound to the endothelial monolayer, anti-CD59 (immunoglobulin G or Fab fragment) potentiated membrane pore formation induced upon C9 binding to C5b-8, and augmented the C5b-9-induced cellular responses, including stimulated secretion of von Willebrand factor and expression of catalytic surface for the prothrombinase enzyme complex. Although potentiating endothelial responses to the terminal complement proteins, anti-CD59 had no effect on the response of these cells to stimulation by histamine. Taken together, these data suggest that human endothelial cells express the CD59 cell surface inhibitor of the terminal complement proteins, which serves to protect these cells from pore-forming and cell-stimulatory effects of the C5b-9 complex. These data also suggest that the inactivation or deletion of this cell surface regulatory molecule would increase the likelihood for procoagulant changes in endothelium exposed to complement activation in plasma.
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104.
K K
KK
Hamilton
Z
Z
Ji
S
S
Rollins
B H
BH
Stewart
P J
PJ
Sims
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D018957:CD59 Antigens; D002462:Cell Membrane / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D003167:Complement Activation; D003182:Complement C5 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology; D050776:Complement C5b; D003186:Complement C9 / Q000378:metabolism; D003165:Complement System Proteins / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D004730:Endothelium, Vascular / Q000737:chemistry / Q000166:cytology* / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006461:Hemolysis / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D008565:Membrane Proteins / Q000032:analysis / Q000378:metabolism / Q000502:physiology; D015539:Platelet Activation / Q000187:drug effects; D013925:Thromboplastin / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D018957:CD59 Antigens; D003182:Complement C5; D003186:Complement C9; D000939:Epitopes; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D014841:von Willebrand Factor; D050776:Complement C5b; D006632:Histamine; D003165:Complement System Proteins; D013925:Thromboplastin